Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | GSR | P00390 | 1/20 | 0.41 |
| ▸ | FBP1 | P09467 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9893480 | 0.86 | GSR (0.42) | KMT2AMEN1MAPTNPSR1GSR | |
| SCHEMBL74691 | 0.83 | SRC (0.48) | GSRCYP2D6SRCLMNAMAPK1 | |
| SCHEMBL11602507 | 0.82 | SRC (0.46) | GSRCYP2D6SRCLMNAMAPK1 | |
| SCHEMBL887039 | 0.82 | SRC (0.46) | GSRCYP2D6SRCLMNAMAPK1 | |
| SCHEMBL5692151 | 0.82 | GSR (0.42) | GSRCYP2D6SRCLMNAMAPK1 | |
| SCHEMBL11602886 | 0.82 | SRC (0.46) | GSRCYP2D6SRCLMNAMAPK1 | |
| SCHEMBL1538911 | 0.82 | CES2 (0.43) | GSRFBP1CYP2D6SRCLMNA | |
| SCHEMBL4423313 | 0.81 | GSR (0.44) | KMT2AMAPTNPSR1GSRCYP2D6 | |
| SCHEMBL11602890 | 0.80 | GSR (0.41) | GSRCYP2D6SRCLMNAMAPK1 | |
| SCHEMBL5682414 | 0.80 | GSR (0.41) | GSRFBP1CYP2D6SRCLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4020059-A | Process for preparing tertiary amines | NIPPON SHOKUBAI KAGAKU KOGYO CO., LTD. (JA) | 1977-04-26 | — | — | US | claimed |
| US-20230357267-A1 | PROCESS FOR PREPARING RELUGOLIX AND INTERMEDIATES THEREOF | SCINOPHARM TAIWAN, LTD. (TW) | 2023-11-09 | — | — | US | disclosed |
| WO-2023214935-A1 | PROCESS FOR PREPARING RELUGOLIX AND INTERMEDIATES THEREOF | SCINOPHARM TAIWAN, LTD. (TW) | 2023-11-09 | — | — | WO | disclosed |
| WO-2021047166-A1 | METHOD FOR SYNTHESIZING TRANYLCYPROMINE INTERMEDIATE | 凯特立斯（深圳）科技有限公司 | 2021-03-18 | — | — | WO | disclosed |
| US-20140155355-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY, INC. | 2014-06-05 | — | — | US | disclosed |
| US-20120015909-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2012-01-19 | — | — | US | disclosed |
| US-7956220-B2 | MAO-B inhibitors useful for treating obesity | JENRIN DISCOVERY (US) | 2011-06-07 | — | — | US | disclosed |
| US-20110028442-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL) PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. (ES) | 2011-02-03 | — | — | US | disclosed |
| EP-2254860-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL) PHENOL AS AGONISTS OF THE B2 ADRENERGIC RECEPTOR | Almirall, S.A. (ES) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009106351-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL) PHENOL AS AGONISTS OF THE B2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. (ES) | 2009-09-03 | — | — | WO | disclosed |
| EP-2096105-A1 | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor | Laboratorios Almirall, S.A. (ES) | 2009-09-02 | — | — | EP | disclosed |
| EP-2064174-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)- OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services (US) | 2009-06-03 | — | — | EP | disclosed |
| CN-101262867-A | MAO-B inhibitors useful for treating obesity | JENRIN DISCOVERY (US) | 2008-09-10 | — | — | CN | disclosed |
| EP-1906952-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | Jenrin Discovery (US) | 2008-04-09 | — | — | EP | disclosed |
| WO-2008022038-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)- OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2007005845-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-01-11 | — | — | WO | disclosed |
| US-20070004683-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-01-04 | — | — | US | disclosed |
| US-4020059-A | Process for preparing tertiary amines | NIPPON SHOKUBAI KAGAKU KOGYO CO., LTD. (JA) | 1977-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015909-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | KMT2A 489/4885MEN1 3464/4885MAPT 2760/4885 |
| US-20070004683-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | KMT2A 489/4885MEN1 3464/4885MAPT 2760/4885 |
| US-20140155355-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | KMT2A 489/4885MEN1 3464/4885MAPT 2760/4885 |
| US-20230357267-A1 | PROCESS FOR PREPARING RELUGOLIX AND INTERMEDIATES THEREOF | PRMT8, PRMT7, PRMT1 | KMT2A 166/4885MEN1 306/4885MAPT 4317/4885 |
| US-20110028442-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL) PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | ADRB2, ADRB1, ADRA2C | KMT2A 2189/4885MEN1 4792/4885MAPT 2590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.